TITLE

Dalfampridine Extended Release Tables (Ampyra)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
March 2010
SOURCE
Internal Medicine Alert;3/29/2010, Vol. 32 Issue 6, p46
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Dalfampridine (Ampyra) drug.
ACCESSION #
49174166

 

Related Articles

  • Ampyra.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article reports that the U.S. Food & Drug Administration (FDA) approved the medication Amprya 10 mg, which aims to increase nerve function and improve walking in patients with multiple sclerosis. Dalfampridine, the generic name of the drug, is a broad-spectrum potassium channel blocker. Drug...

  • Dalfampridine approved for MS. Traynor, Kate // American Journal of Health-System Pharmacy;3/1/2010, Vol. 67 Issue 5, p335 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of dalfampridine or Ampyra as an oral therapy for the walking improvement of patients with multiple sclerosis (MS) in the U.S. It describes dalfampridine as a potassium channel blocker which increases the...

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

  • Slew of approvables.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p27 

    Lists several approval drugs by the U.S. Food and Drug Administration. Ranexa to treat chronic angina; Insulin determir, a long-acting form of the diabetes drug; Fortament, an extended-release product to lower blood glucose.

  • FDA actions in brief.  // Formulary;Feb2010, Vol. 45 Issue 2, p42 

    The article discusses news briefs about drugs approved by the U.S. Food and Drug Administration (FDA). The drugs include dalfampridine extended release tablets, tocilzumab and morphine sulfate oral solution.

  • Pipeline preview.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article offers U.S. Food & Drug Administration (FDA) drug approval news briefs. Miglustat has been approved for the treatment of Niemann-Pick type C disease, pirfenidone has been recommended for approval to improve lung function and pixantrone has been recommended not to be approved.

  • FDA actions in brief.  // Formulary;Apr2010, Vol. 45 Issue 4, p114 

    The article presents a list of drugs approved by the U.S. Food & Drug Administration (FDA) including doxepin for the treatment of insomnia, adapalene lotion for the treatment of acne and somatropin injection for the treatment of growth hormone disorders.

  • New molecular entities/biologics.  // Formulary;Feb2003, Vol. 38 Issue 2, p78 

    Reports on drugs approved by the U.S. Food and Drug Administration as of February 2003. Extraneal; Humira.

  • FDA Drug Approvals.  // Formulary;Jul2003, Vol. 38 Issue 7, p392 

    Reports on the U.S. Food and Drug Administration's approval of various drugs, as of July 2003. Boniva; Xolair; FluMist.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics